Department of Obstetrics and Gynecology and.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
J Low Genit Tract Dis. 2018 Oct;22(4):362-366. doi: 10.1097/LGT.0000000000000414.
The ideal frequency of cervical cancer screening in women with solid organ transplants (SOTs) remains to be determined. We aimed to assess the longitudinal rates of cytologic and histologic cervical abnormalities in women after SOT.
We retrospectively reviewed health records of women aged 18 to 60 years who received their first kidney, liver, pancreas, or combination transplant at Mayo Clinic (Rochester, Minnesota) from 1995 through 2011. Patient demographics, cervical cytology and histology, and high-risk human papillomavirus (hrHPV) testing data were abstracted. All women included in the study had documentation of at least 1 cervical cytologic assessment after SOT. Cumulative incidence of abnormal cytology or histology was estimated using the Kaplan-Meier method.
In total, 459 women (mean age at SOT, 43.9 years) were included in the study. Pre-SOT cytology was benign in 226 (97.4%) of 232 patients with available results. During follow-up, 9 women had cervical intraepithelial neoplasia grade 3 or higher (CIN3) histology. The cumulative incidence of CIN3 was 0.2% (95% confidence interval [CI], 0%-0.6%) at 1 year after SOT, 0.7% (95% CI, 0%-1.5%) at 2 years, 1.9% (95% CI, 0.5%-3.3%) at 5 years, and 3.1% (95% CI, 0.4%-5.7%) at 10 years. At the time of the first post-SOT cervical cytology, a greater proportion of women who were hrHPV positive had abnormal findings compared with hrHPV-negative women (10/15 [66.7%] vs 1/71 [1.4%]; p < .001).
The cumulative incidence of CIN3 in the first 5 years after SOT approximates the level of risk for which annual cytologic assessment has been recommended.
在实体器官移植(SOT)女性中,宫颈癌筛查的理想频率仍有待确定。我们旨在评估 SOT 后女性细胞学和组织学宫颈异常的纵向发生率。
我们回顾性地审查了 1995 年至 2011 年在明尼苏达州罗切斯特的梅奥诊所接受首次肾、肝、胰腺或联合移植的 18 至 60 岁女性的健康记录。提取患者人口统计学、宫颈细胞学和组织学以及高危型人乳头瘤病毒(hrHPV)检测数据。所有纳入研究的女性均有 SOT 后至少 1 次宫颈细胞学评估的记录。使用 Kaplan-Meier 方法估计异常细胞学或组织学的累积发生率。
共有 459 名女性(SOT 时的平均年龄为 43.9 岁)纳入研究。有 232 名患者(可获得结果)的 Pre-SOT 细胞学为良性,占 97.4%。在随访期间,9 名女性患有宫颈上皮内瘤变 3 级或更高级别(CIN3)组织学。SOT 后 1 年时 CIN3 的累积发生率为 0.2%(95%CI,0%-0.6%),2 年时为 0.7%(95%CI,0%-1.5%),5 年时为 1.9%(95%CI,0.5%-3.3%),10 年时为 3.1%(95%CI,0.4%-5.7%)。在首次 SOT 后宫颈细胞学检查时,hrHPV 阳性的女性异常发现的比例高于 hrHPV 阴性的女性(15 例中有 10 例[66.7%]与 71 例中有 1 例[1.4%];p <.001)。
SOT 后 5 年内 CIN3 的累积发生率接近推荐每年进行细胞学评估的风险水平。